Shares of Novavax Inc. were up 2.4% in premarket trading on Friday after the company said its COVID-19 booster was authorized for adults in Canada who were previously immunized with Novavax’s protein-based vaccine. The company’s stock is down 85.4% this year, while the S&P 500 has declined 17.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.